NACDS prepared and delivered verbal and written testimony before the House of Representatives Behavioral Health and Health Care Committee in full support of HB 3212. Additionally, the testimony included how this crucial bill aims to reform PBMs and address their dangerous tactics that threaten the vitality of neighborhood pharmacies and patient access. Specifically, HB 3212 would prohibit spread pricing and patient steering, restrict PBMs from mandating pharmacies to provide a health care service at a loss, prohibit PBMs from requiring further accreditation standards beyond those currently required by the Oregon Board of Pharmacy, help to ensure network adequacy, and most importantly, help to ensure reasonable and relevant reimbursement to community pharmacies that covers the true costs for pharmacies to purchase and dispense prescription drugs. NACDS urged lawmakers to advance HB 3212 to help ensure reasonable pharmacy reimbursement and protect patients’ access to trusted pharmaceutical care across the state.

Also in Oregon, the Prescription Drug Affordability Board held a meeting on February 19. Generally, the agenda and materials for this meeting was focused on policies, processes, and administrative matters, plus a legislative update. Register here in advance.

Also in Oregon, the Oregon Health Authority (OHA) published proposed rules establishing guidelines for enhanced payment to qualified providers under the Culturally and Linguistic Specific Services program. A 22 percent and 27 percent increase in fee-for-service payments for traditional health worker providers, programs, and organizations in urban and rural areas, respectively, will enable OHA to continue investments to improve access to care, incentivize culturally and linguistically specific services, invest in workforce diversity and support staff recruitment.

Also in Oregon, the Board of Pharmacy posted the agenda for the February 24 Executive Director Recruitment Subcommittee Meeting.

Also in Oregon, the Immunization Policy Advisory Team will meet on March 6. Draft agenda items include welcome, introductions of new members; public comment; respiratory season wrap-up—COVID-19, influenza, pertussis, RSV; data dashboards; legislation update; Project Horizon—program resize; ALERT IIS Replacement Project update; school requirements—new administrative rules; wrap-up. The final agenda will be available at the meeting or via email request three days before the meeting date.

Finally in Oregon, on February 6, the Board of Pharmacy adopted a statement on semaglutide.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.